Brightstar Therapeutics

Recent Finacing

Series A

Recent Raise

Undisclosed

Brightstar Therapeutics (Lexington, KY) develops BrightMEM, an advanced corneal allograft that regenerates epithelium and protects stroma to treat persistent epithelial defects and partial limbal stem cell deficiency.

Founded 2023

Kentucky, United States

1-10

Private

brightstartx.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Therapeutics

Recent Investors

I

Financials

1

Funding round

4

Investors

Team

Upgrade to view the team

See the team members at Brightstar Therapeutics.